BIOTECH CONSORTIUM INDIA LIMITED

NANOPARTICLES FOR EFFICIENT DRUG DELIVERY

TECHNOLOGY AVAILABLE FOR TRANSFER

TECHNOLOGY

A novel nanoparticle formulation of transferrins i.e. apotransferrin and lactoferrin and processes for pre-paring them for oral and IV delivery of approved drugs. Localisation of drug was significantly higher in affected cells. Efficacy is evaluated in liver cancer only. Future work is on indications like breast cancer, eye localisation and other similar conditions.

The technology has been developed at the Department of Biotechnology, University of Hyderabad.

COMPETITIVE ADVANTAGES

- The Composition is effective for the delivery of cancer drugs and neuro active agents
- The apotransferrin / transferrin is readily available after the delivery of the drug contained in the composition
- There is no chemical conjugation of the drug and apotransferrin / transferring, facilitating easy drug delivery
- Do not induce any cytotoxicity on the patients
- Nano-formulation decreased the cardio toxicity of drugs like Doxorubicin.
- Increased localisation of drugs in liver .
- Higher capacity of drug loading at more that 60%

APPLICATIONS

Nano-medicine formulations of various drugs for treatment of many ailments from cancer to infectious diseases

STATE OF DEVELOPMENT

The processes are developed till lab scale with formulations tested in pre-clinical and animal assays

INTELLECTUAL PROPERTY

Patent Pending

LICENSING OPPORTUNITY

BCIL is looking for a suitable company involved developing novel drug delivery formulations especially nano-particles based formulations.

CONTACT:
MANAGER (IP AND TECHNOLOGY TRANSFER CELL)
BIOTECH CONSORTIUM INDIA LIMITED
V Floor, Anuvrat Bhawan
210, Deen Dayal Upadhyaya Marg
New Delhi:110 002
Phone: +91-11-23219064-67, 23219053 (Direct) Fax: +91-11-23219063
Email: info.bcil@nic.in Website: www.bcil.nic.in